Company intelligence / Profile preview

盛迪医药

Chengdu, Sichuan, Chinaen.wikipedia.org ↗

Ownership: Private
Development stage: Other

Overview

盛迪医药（Shengdi Pharma）is a well-known Chinese pharmaceutical company focused on R&D and commercialization of innovative drugs and high-quality generics. It has launched at least thirteen self-developed innovative drugs and two co-developed innovative drugs in China. The company supplies anti-tumor medications, perioperative medicines, and interventional imaging products. Its affiliated companies have achieved commercial approvals for key oncology biologic products such as a bevacizumab biosimilar targeting metastatic colorectal cancer and advanced/metastatic/recurrent non-small cell lung cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Pharma

Beyond the preview

Go deeper on 盛迪医药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 盛迪医药.

Explore the full profile